<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37055095</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8607</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Immunology and allergy clinics of North America</Title><ISOAbbreviation>Immunol Allergy Clin North Am</ISOAbbreviation></Journal><ArticleTitle>Post-COVID Interstitial Lung Disease-The Tip of the Iceberg.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>410</EndPage><MedlinePgn>389-410</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.iac.2023.01.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0889-8561(23)00004-8</ELocationID><Abstract><AbstractText>The proportion of symptomatic patients with post-coronavirus 2019 (COVID-19) condition (long COVID) represents a significant burden on the individual as well as on the health care systems. A greater understanding of the natural evolution of symptoms over a longer period and the impacts of interventions will improve our understanding of the long-term impacts of the COVID-19 disease. This review will discuss the emerging evidence for the development of post-COVID interstitial lung disease focusing on the pathophysiological mechanisms, incidence, diagnosis, and impact of this potentially new and emerging respiratory disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kewalramani</LastName><ForeName>Namrata</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department for BioMedical Research DBMR, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. Electronic address: Namrata.kewalramani@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heenan</LastName><ForeName>Kerri-Marie</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Antrim Area Hospital, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeegan</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Antrim Area Hospital, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>Nazia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University of Ulster Magee Campus, Northland Road, Londonderry, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Immunol Allergy Clin North Am</MedlineTA><NlmUniqueID>8805635</NlmUniqueID><ISSNLinking>0889-8561</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012120" MajorTopicYN="Y">Respiration Disorders</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Interstitial lung disease</Keyword><Keyword MajorTopicYN="N">Long-term impact</Keyword><Keyword MajorTopicYN="N">Post-COVID fibrosis</Keyword><Keyword MajorTopicYN="N">Post-COVID-19 condition (long COVID)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>20</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37055095</ArticleId><ArticleId IdType="pmc">PMC9982726</ArticleId><ArticleId IdType="doi">10.1016/j.iac.2023.01.004</ArticleId><ArticleId IdType="pii">S0889-8561(23)00004-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ghebreyesus TA. WHO Director-General&#x2019;s opening remarks at the media briefing on COVID-19. In: World Health Organization. 2020. Available at WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. Accessed September 9, 2022.</Citation></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., et al. A&#xa0;Novel Coronavirus from Patients with Pneumonia in China, 2019. N&#xa0;Engl J Med. 2020;382(8):727&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. In: World Health Organization 2022. Available at WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Accessed September 9, 2022.</Citation></Reference><Reference><Citation>Gao Y., Ding M., Dong X., et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild J.M., Porter J.C., Molyneaux P.L., et al. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID) BMJ Open Respiratory Research. 2021;8(1):e001049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461362</ArticleId><ArticleId IdType="pubmed">34556492</ArticleId></ArticleIdList></Reference><Reference><Citation>Dro&#x17c;d&#x17c;al S., Rosik J., Lechowicz K., et al. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updates. 2021;59:100794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8654464</ArticleId><ArticleId IdType="pubmed">34991982</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D. v. Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 Infection in non-hospitalized patients. Med Sci Mon Int Med J Exp Clin Res. 2022;28:e935952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8729033</ArticleId><ArticleId IdType="pubmed">34972812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., et al. Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N&#xa0;Engl J Med. 2022;386(15):1397&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W.A. 2nd., Eron J.J., Jr., et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763622</ArticleId><ArticleId IdType="pubmed">34941423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd I., Kumar Arora M., Asdaq S.M.B., et al. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19. Molecules. 2021;26(19):5795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510125</ArticleId><ArticleId IdType="pubmed">34641339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.</Citation><ArticleIdList><ArticleId IdType="pubmed">34607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) latest insights. In:Office for National Statistics 2022. Available at Coronavirus (COVID-19) latest insights - Office for National Statistics (ons.gov.uk). Accessed September 10, 2022.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. CDC COVID Data Tracker: Daily and Total Trends. In: Centers for Disease Control and Prevention 2022. Available at CDC COVID Data Tracker: Daily and Total Trends. Accessed August 25, 2022.</Citation></Reference><Reference><Citation>George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Barratt S.L., Condliffe R., et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">32839287</ArticleId></ArticleIdList></Reference><Reference><Citation>Das K.M., Lee E.Y., Singh R., et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imag. 2017;27(03):342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5644332</ArticleId><ArticleId IdType="pubmed">29089687</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie L., Liu Y., Fan B., et al. Dynamic changes of serum SARS-Coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respir Res. 2005;6(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC545044</ArticleId><ArticleId IdType="pubmed">15638943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Liu X., Zhou Y., et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Wang X., Xiong Y., et al. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine. 2021;100(12):e25232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282075</ArticleId><ArticleId IdType="pubmed">33761714</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsana L., Sonzogni A., Nasr A., et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279758</ArticleId><ArticleId IdType="pubmed">32526193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducloyer M., Gaborit B., Toquet C., et al. Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations. Int J Legal Med. 2020;134(6):2209&#x2013;2214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410356</ArticleId><ArticleId IdType="pubmed">32767018</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo F., Barisione E., Ball L., et al. Lung fibrosis: an undervalued finding in COVID-19 pathological series. Lancet Infect Dis. 2021;21(4):e72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386839</ArticleId><ArticleId IdType="pubmed">32735785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun P., Qie S., Liu Z., et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis. J&#xa0;Med Virol. 2020;92(6):612&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228255</ArticleId><ArticleId IdType="pubmed">32108351</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P., Bos L.D. Pathophysiology of the acute respiratory distress syndrome. Crit Care Clin. 2021;37(4):795&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149201</ArticleId><ArticleId IdType="pubmed">34548134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Shih T.P., Ko W.C., et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127800</ArticleId><ArticleId IdType="pubmed">32081636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcdonald L.T. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320(2):L257&#x2013;L265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900916</ArticleId><ArticleId IdType="pubmed">33355522</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware L.B., Matthay M.A. The Acute Respiratory Distress Syndrome. N&#xa0;Engl J Med. 2000;342(18):1334&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793167</ArticleId></ArticleIdList></Reference><Reference><Citation>Thille A.W., Esteban A., Fern&#xe1;ndez-Segoviano P., et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Respir Med. 2013;1(5):395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">24429204</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C., Li H., Bao M., et al. Alveolar macrophage - derived exosomes modulate severity and outcome of acute lung injury. Aging. 2020;12(7):6120&#x2013;6128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185135</ArticleId><ArticleId IdType="pubmed">32259794</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Herbert J.A., Robinson E., et al. Neutrophil-airway epithelial interactions result in increased epithelial damage and viral clearance during respiratory syncytial virus infection. J&#xa0;Virol. 2020;94(13) 021611&#x2013;e2219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307165</ArticleId><ArticleId IdType="pubmed">32295918</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert J.A., Deng Y., Hardelid P., et al. &#x3b2; 2 -integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection. Eur Respir J. 2020;56(2):1902216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406857</ArticleId><ArticleId IdType="pubmed">32217648</ArticleId></ArticleIdList></Reference><Reference><Citation>John A.E., Joseph C., Jenkins G., et al. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302(1):228&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237078</ArticleId><ArticleId IdType="pubmed">34028807</ArticleId></ArticleIdList></Reference><Reference><Citation>Melms J.C., Biermann J., Huang H., et al. A&#xa0;molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595(7865):114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8814825</ArticleId><ArticleId IdType="pubmed">33915568</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Yao X., Ma S., et al. A&#xa0;single-cell transcriptomic landscape of the lungs of patients with COVID-19. Nat Cell Biol. 2021;23(12):1314&#x2013;1328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8650955</ArticleId><ArticleId IdType="pubmed">34876692</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Zhao W., Li J.W., et al. Discharge may not be the end of treatment: pay attention to pulmonary fibrosis caused by severe COVID-19. J&#xa0;Med Virol. 2021;93:1378&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">33107641</ArticleId></ArticleIdList></Reference><Reference><Citation>Piersma B., Bank R.A., Boersema M. Signaling in Fibrosis: TGF-&#x3b2;, WNT, and YAP/TAZ Converge. Front Med (Lausanne) 2015;2:59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4558529</ArticleId><ArticleId IdType="pubmed">26389119</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Ben&#xed;tez N.E., Parotto M., Post M., et al. Mechanical stress induces lung fibrosis by epithelial&#x2013;mesenchymal transition&#x2217;. Crit Care Med. 2012;40(2):510&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061566</ArticleId><ArticleId IdType="pubmed">21926573</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Pan Y., Fanelli V., et al. Mechanical stress and the induction of lung fibrosis via the midkine signaling pathway. Am J Respir Crit Care Med. 2015;192(3):315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">25945397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Yang H., Lei P., et al. Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge. J&#xa0;X Ray Sci Technol. 2020;28(3):383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369060</ArticleId><ArticleId IdType="pubmed">32474479</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188). In:London: National Institute for Health and Care Excellence (NICE). 2021. Available at Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance | NICE. Accessed September 10, 2022.</Citation></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., et al. &#x2018;Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalization for COVID-19. Thorax. 2021;76(4):396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., McAuley H., Harrison E.M., et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., Leavy O.C., Richardson M., et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas Centanaro G., Calle Rubio M., &#xc1;lvarez-Sala Walther J.L., Martinez-Sagasti F., Albuja Hidalgo A., Herranz Hern&#xe1;ndez R., Rodr&#xed;guez Hermosa J.L. Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study. Open Forum Infect Dis. 2022;9(4):ofac098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903519</ArticleId><ArticleId IdType="pubmed">35360197</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun H.J., Coutavas E., Pine A.B., et al. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight. 2021;6(14)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410030</ArticleId><ArticleId IdType="pubmed">34111030</ArticleId></ArticleIdList></Reference><Reference><Citation>Willi S., L&#xfc;thold R., Hunt A., et al. COVID-19 sequelae in adults aged less than 50 years: a systematic review. Trav Med Infect Dis. 2021;40:101995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7898978</ArticleId><ArticleId IdType="pubmed">33631340</ArticleId></ArticleIdList></Reference><Reference><Citation>Froidure A., Mahsouli A., Liistro G., et al. Integrative respiratory follow-up of severe COVID-19 reveals common functional and lung imaging sequelae. Respir Med. 2021;181:106383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019490</ArticleId><ArticleId IdType="pubmed">33839588</ArticleId></ArticleIdList></Reference><Reference><Citation>Boari G.E.M., Bonetti S., Braglia-Orlandini F., et al. Short-Term Consequences of SARS-CoV-2-Related Pneumonia: A Follow Up Study. High Blood Pres Cardiovasc Prev. 2021;28(4):373&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080190</ArticleId><ArticleId IdType="pubmed">33909284</ArticleId></ArticleIdList></Reference><Reference><Citation>Robey R.C., Kemp K., Hayton P., et al. Pulmonary sequelae at 4&#xa0;months After COVID-19 infection: a single-centre experience of a COVID Follow-Up Service. Adv Ther. 2021;38(8):4505&#x2013;4519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286847</ArticleId><ArticleId IdType="pubmed">34278556</ArticleId></ArticleIdList></Reference><Reference><Citation>Faverio P., Luppi F., Rebora P., et al. Six-month pulmonary impairment after severe COVID-19: a prospective, multicentre follow-up study. Respiration. 2021;100(11):1078&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450855</ArticleId><ArticleId IdType="pubmed">34515212</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Fan Y., Alwalid O., et al. Six-month follow-up chest CT Findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177&#x2013;E186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama Amin B.J., Kakamad F.H., Ahmed G.S., et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Annals of Medicine and Surgery. 2022;77:103590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8983072</ArticleId><ArticleId IdType="pubmed">35411216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A., Belletti A., Palumbo D., et al. One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation. J&#xa0;Cardiothorac Vasc Anesth. 2022;36(5):1354&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626145</ArticleId><ArticleId IdType="pubmed">34973891</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398(10302):747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Faverio P., Luppi F., Rebora P., et al. One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study. Respir Res. 2022;23(1):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934910</ArticleId><ArticleId IdType="pubmed">35313890</ArticleId></ArticleIdList></Reference><Reference><Citation>Eksombatchai D., Wongsinin T., Phongnarudech T., et al. Pulmonary function and six-minute-walk test in patients after recovery from COVID-19: A prospective cohort study. PLoS One. 2021;16(9):e0257040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412277</ArticleId><ArticleId IdType="pubmed">34473811</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv D., Chen X., Wang X., et al. Pulmonary function of patients with 2019 novel coronavirus induced-pneumonia: a retrospective cohort study Ann Palliat Med. 2020;9(5):3447&#x2013;3452.</Citation><ArticleIdList><ArticleId IdType="pubmed">33065795</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A.S., Wong A.W., Hague C.J., et al. A&#xa0;prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">33273023</ArticleId></ArticleIdList></Reference><Reference><Citation>Frija-Masson J., Debray M.P., Boussouar S., et al. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study. Respir Med. 2021;184:106435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123365</ArticleId><ArticleId IdType="pubmed">34020126</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler S.A., Ebner L., Aubry-Beigelman C., et al. Pulmonary function and radiological features 4&#xa0;months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4):2003690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel-Savina E., Viatg&#xe9; T., Faviez G., et al. Severe SARS-CoV-2 pneumonia: clinical, functional and imaging outcomes at 4&#xa0;months. Respiratory Medicine and Research. 2021;80:100822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080504</ArticleId><ArticleId IdType="pubmed">34242974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellemons M.E., Huijts S., Bek L.M., et al. Persistent health problems beyond pulmonary recovery up to 6&#xa0;months after hospitalization for COVID-19: a longitudinal study of respiratory, physical, and psychological outcomes. Annals of the American Thoracic Society. 2022;19(4):551&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8996273</ArticleId><ArticleId IdType="pubmed">34582728</ArticleId></ArticleIdList></Reference><Reference><Citation>Safont B., Tarraso J., Rodriguez-Borja E., et al. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. Arch Bronconeumol. 2022;58(2):142&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414844</ArticleId><ArticleId IdType="pubmed">34497426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarraso J., Safont B., Carbonell-Asins J.A., et al. Lung function and radiological findings 1 year after COVID-19: a prospective follow-up. Respir Res. 2022;23(1):242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9466319</ArticleId><ArticleId IdType="pubmed">36096801</ArticleId></ArticleIdList></Reference><Reference><Citation>Marvisi M., Ferrozzi F., Balzarini L., et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. Int J Infect Dis. 2020;99:485&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7443096</ArticleId><ArticleId IdType="pubmed">32841688</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z.L., Chen C., Huang L., et al. Fibrotic changes depicted by thin-section CT in patients With COVID-19 at the early recovery stage: preliminary experience. Front Med. 2020;7:605088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7732534</ArticleId><ArticleId IdType="pubmed">33330571</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M., Xu J., Liao T., et al. Comparison of residual pulmonary abnormalities 3&#xa0;months after discharge in patients who recovered from COVID-19 of Different severity. Front Med. 2021;8:682087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270002</ArticleId><ArticleId IdType="pubmed">34249973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocconcelli E., Bernardinello N., Giraudo C., et al. Characteristics and prognostic factors of pulmonary fibrosis After COVID-19 pneumonia. Front Med. 2022;8:823600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8841677</ArticleId><ArticleId IdType="pubmed">35174188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Zhang C., Li X., et al. Thin-section computed tomography findings and longitudinal variations of the residual pulmonary sequelae after discharge in patients with COVID-19: a short-term follow-up study. Eur Radiol. 2021;31(9):7172&#x2013;7183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7950423</ArticleId><ArticleId IdType="pubmed">33704519</ArticleId></ArticleIdList></Reference><Reference><Citation>Besutti G., Monelli F., Schir&#xf2; S., et al. Follow-Up CT patterns of residual lung abnormalities in severe COVID-19 pneumonia survivors: a multicenter retrospective study. Tomography. 2022;8(3):1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9149852</ArticleId><ArticleId IdType="pubmed">35645383</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis T.J.M., Heiden E., Horno J., et al. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. Respir Res. 2021;22(1):157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139368</ArticleId><ArticleId IdType="pubmed">34020644</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso D., Guido G., Zerunian M., et al. Post-acute sequelae of COVID-19 pneumonia: six-month chest CT follow-up. Radiology. 2021;301(2):E396&#x2013;E405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335814</ArticleId><ArticleId IdType="pubmed">34313468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri L., Moss S., Khan F.A., et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2022;78(2):191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">35338102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchino M., Lieto R., Romano F., et al. Chest CT-based assessment of 1-year outcomes after moderate COVID-19 pneumonia. Radiology. 2022;305(2):479&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619196</ArticleId><ArticleId IdType="pubmed">35536134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., Rosas I.O., Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med. 2022;48(12):1803&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9453725</ArticleId><ArticleId IdType="pubmed">36074167</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with Covid-19. N&#xa0;Engl J Med. 2021;384(8):693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall K.J., Mukherjee B., Castanheira A.M., et al. Persistent post&#x2013;COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Annals of the American Thoracic Society. 2021;18(5):799&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Saiphoklang N., Patanayindee P., Ruchiwit P. The effect of NINTEDANIB in Post-COVID-19 lung fibrosis: an observational study. Critical Care Research and Practice. 2022;2022:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9529527</ArticleId><ArticleId IdType="pubmed">36199668</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina M. Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19. In: ClinicalTrials.gov. 2021. Available at Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19-Full Text View - ClinicalTrials.gov. Accessed October 10, 2022.</Citation></Reference><Reference><Citation>Krishna Murthy P., Sivashanmugam K., Kandasamy M., et al. Repurposing of histone deacetylase inhibitors: a promising strategy to combat pulmonary fibrosis promoted by TGF-&#x3b2; signalling in COVID-19 survivors. Life Sci. 2021;266:118883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831549</ArticleId><ArticleId IdType="pubmed">33316266</ArticleId></ArticleIdList></Reference><Reference><Citation>Vishnupriya M., Naveenkumar M., Manjima K., et al. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells - How the lung heals. Eur Rev Med Pharmacol Sci. 2021;25(6):2748&#x2013;2751.</Citation><ArticleIdList><ArticleId IdType="pubmed">33829461</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Zhou X., Tan Y., et al. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs. Cell Prolif. 2020;53(12):e12944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645925</ArticleId><ArticleId IdType="pubmed">33107132</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Chicago. Assessing the Efficacy of Sirolimus in Patients with COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis. In:ClinicalTrials.gov. 2021, Available at Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis - Full Text View - ClinicalTrials.gov. Accessed October 10, 2022.</Citation></Reference><Reference><Citation>Issak ER. Colchicine and Post-COVID-19 Pulmonary Fibrosis. In: ClinicalTrials.gov, 2021. Available at Colchicine and Post-COVID-19 Pulmonary Fibrosis - Full Text View - ClinicalTrials.gov. Accessed October 10, 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>